Azitra (AZTR) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZTR | NRSN |
|---|---|---|
| Share price | $0.5168 | $1.28 |
| Market cap | $3.13M | $3.19M |
| 1-day change | -2.75% | +1.59% |
| EPS (TTM) | $-12.40 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-10.96M | $-11.13M |
| 52-week high | $3.91 | $24.80 |
| 52-week low | $0.5086 | $1.10 |
| Distance from 52-week high | -86.78% | -94.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +29.64% | +7503.91% |
| Average volume | 2.65M | 31.57K |
| Shares outstanding | 6.06M | 2.49M |
| Employees | 13 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Azitra
AZTR stock →Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
AZTR vs NRSN FAQ
Which is bigger, Azitra or NeuroSense Therapeutics?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $3.19M compared with $3.13M for Azitra (AZTR).
Are Azitra and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.